ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $66,811,000 | -21.1% | 518,396 | +2.1% | 0.07% | -27.7% |
| Q4 2020 | $84,684,000 | +50.2% | 507,758 | +39.0% | 0.09% | +30.6% |
| Q3 2020 | $56,391,000 | -4.3% | 365,417 | -8.3% | 0.07% | -10.0% |
| Q2 2020 | $58,929,000 | -34.8% | 398,438 | -50.4% | 0.08% | +5.3% |
| Q1 2020 | $90,432,000 | +19.3% | 803,052 | +47.4% | 0.08% | -17.4% |
| Q4 2019 | $75,815,000 | +79.5% | 544,965 | +24.3% | 0.09% | +70.4% |
| Q3 2019 | $42,238,000 | +7.6% | 438,514 | +28.6% | 0.05% | -31.6% |
| Q2 2019 | $39,256,000 | +3.3% | 340,908 | +5.6% | 0.08% | -8.1% |
| Q1 2019 | $37,984,000 | +2499.9% | 322,718 | +1284.0% | 0.09% | +2050.0% |
| Q4 2018 | $1,461,000 | -13.1% | 23,318 | -1.8% | 0.00% | +33.3% |
| Q3 2018 | $1,682,000 | +1.2% | 23,738 | -5.0% | 0.00% | -25.0% |
| Q2 2018 | $1,662,000 | -3.5% | 24,978 | -5.2% | 0.00% | 0.0% |
| Q1 2018 | $1,723,000 | +147.6% | 26,338 | +51.6% | 0.00% | +300.0% |
| Q4 2017 | $696,000 | +258.8% | 17,368 | +224.2% | 0.00% | – |
| Q3 2017 | $194,000 | +34.7% | 5,358 | +3.9% | 0.00% | – |
| Q1 2017 | $144,000 | – | 5,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |